CN109069498B - 四氢异喹啉衍生物 - Google Patents

四氢异喹啉衍生物 Download PDF

Info

Publication number
CN109069498B
CN109069498B CN201780010949.1A CN201780010949A CN109069498B CN 109069498 B CN109069498 B CN 109069498B CN 201780010949 A CN201780010949 A CN 201780010949A CN 109069498 B CN109069498 B CN 109069498B
Authority
CN
China
Prior art keywords
compound
alkyl
salt
substituted
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780010949.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN109069498A (zh
Inventor
佐藤一平
上久保隆
三浦理宪
松岛雄司
田中宏明
椎名康裕
山木晋
斋藤智之
清原宏
大江宗理
三原佳代子
布莱利·保罗·摩根
费迪·马里克
史考特·艾米勒·柯利比
路加·艾席克莱夫
吕卜平
杰佛瑞·迈克尔·沃林顿
马克·贾瑞德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokinetics Inc
Original Assignee
Astellas Pharma Inc
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Cytokinetics Inc filed Critical Astellas Pharma Inc
Priority to CN202110837700.6A priority Critical patent/CN113666938A/zh
Publication of CN109069498A publication Critical patent/CN109069498A/zh
Application granted granted Critical
Publication of CN109069498B publication Critical patent/CN109069498B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201780010949.1A 2016-02-12 2017-02-10 四氢异喹啉衍生物 Expired - Fee Related CN109069498B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110837700.6A CN113666938A (zh) 2016-02-12 2017-02-10 四氢异喹啉衍生物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662285039P 2016-02-12 2016-02-12
US62/285,039 2016-02-12
PCT/US2017/017295 WO2017139526A1 (en) 2016-02-12 2017-02-10 Tetrahydroisoquinoline derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110837700.6A Division CN113666938A (zh) 2016-02-12 2017-02-10 四氢异喹啉衍生物

Publications (2)

Publication Number Publication Date
CN109069498A CN109069498A (zh) 2018-12-21
CN109069498B true CN109069498B (zh) 2021-08-17

Family

ID=59561239

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780010949.1A Expired - Fee Related CN109069498B (zh) 2016-02-12 2017-02-10 四氢异喹啉衍生物
CN202110837700.6A Pending CN113666938A (zh) 2016-02-12 2017-02-10 四氢异喹啉衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110837700.6A Pending CN113666938A (zh) 2016-02-12 2017-02-10 四氢异喹啉衍生物

Country Status (34)

Country Link
US (5) US9914741B2 (https=)
EP (2) EP4032877A1 (https=)
JP (2) JP6832943B2 (https=)
KR (1) KR20180120701A (https=)
CN (2) CN109069498B (https=)
AR (1) AR107592A1 (https=)
AU (1) AU2017217663B2 (https=)
BR (1) BR112018016475A2 (https=)
CA (1) CA3012839A1 (https=)
CL (1) CL2018002287A1 (https=)
CO (1) CO2018007920A2 (https=)
CY (1) CY1125222T1 (https=)
DK (1) DK3413892T3 (https=)
ES (1) ES2913423T3 (https=)
HR (1) HRP20220655T1 (https=)
HU (1) HUE058820T2 (https=)
IL (1) IL261055B (https=)
LT (1) LT3413892T (https=)
MA (1) MA44018B1 (https=)
MD (1) MD3413892T2 (https=)
MX (1) MX379159B (https=)
NZ (1) NZ746311A (https=)
PH (1) PH12018501694B1 (https=)
PL (1) PL3413892T3 (https=)
PT (1) PT3413892T (https=)
RS (1) RS63240B1 (https=)
RU (1) RU2743424C2 (https=)
SG (1) SG11201806416XA (https=)
SI (1) SI3413892T1 (https=)
SM (1) SMT202200201T1 (https=)
TW (2) TWI773118B (https=)
UA (1) UA124879C2 (https=)
WO (1) WO2017139526A1 (https=)
ZA (1) ZA201804947B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018016475A2 (en) * 2016-02-12 2018-12-26 Cytokinetics, Incorporated tetrahydroisoquinoline derivatives
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
WO2022099011A1 (en) * 2020-11-06 2022-05-12 Cytokinetics, Inc. Bicyclic 1,4-diazepanones and therapeutic uses thereof
WO2025080100A1 (ko) * 2023-10-11 2025-04-17 한국화학연구원 신규한 디-아미드 화합물, 이의 제조방법, 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
CN117379425A (zh) * 2023-11-14 2024-01-12 广州日聚商贸发展有限公司 喹啉-4-羧酸在抗衰老产品以及保护肝脏、促进肝脏再生产品制备中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009108332A1 (en) * 2008-02-27 2009-09-03 Vitae Pharmaceuticals, Inc. INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1
CN102993204A (zh) * 2006-08-02 2013-03-27 赛特凯恩蒂克公司 特定的化学个体、组合物和方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3301857A (en) 1963-08-26 1967-01-31 Hoffmann La Roche Spiro
SE368009B (https=) 1971-09-16 1974-06-17 Kabi Ab
US6492520B1 (en) * 1996-08-06 2002-12-10 Pfizer Inc Substituted pyrido-or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
KR100567649B1 (ko) 1996-09-25 2006-04-05 아스트라제네카 유케이 리미티드 혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체
US6410254B1 (en) 1999-05-18 2002-06-25 Cytokinetics Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US6743599B1 (en) 1999-05-18 2004-06-01 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US7202051B1 (en) 1999-05-18 2007-04-10 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US6958333B1 (en) * 1999-07-26 2005-10-25 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
JP2001106673A (ja) * 1999-07-26 2001-04-17 Banyu Pharmaceut Co Ltd ビアリールウレア誘導体
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
JP4361566B2 (ja) * 2004-04-28 2009-11-11 武田薬品工業株式会社 縮合キノリン誘導体およびその使用
WO2007075783A2 (en) * 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor
GB0613208D0 (en) 2006-07-03 2006-08-09 Glaxo Group Ltd Compounds
NZ577980A (en) * 2006-12-27 2012-01-12 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
RU2443698C2 (ru) 2007-01-05 2012-02-27 Дайити Санкио Компани, Лимитед Конденсированное замещенное производное аминопирролидина
US8163909B2 (en) 2007-05-25 2012-04-24 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
CN101518971B (zh) * 2008-02-29 2012-07-18 E.I.内穆尔杜邦公司 聚酯叠层膜和使用该叠层膜的太阳能电池板
NZ592008A (en) * 2008-10-02 2011-12-22 Taisho Pharmaceutical Co Ltd 7-piperidinoalkyl-3,4-dihydroquinolone derivative
CN102256493A (zh) 2008-10-29 2011-11-23 迪赛孚尔制药有限公司 表现出抗癌活性和抗增殖活性的环丙烷酰胺及其类似物
WO2010131145A1 (en) 2009-05-12 2010-11-18 Pfizer Limited Cyclobutenedione derivatives
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
CN103476757A (zh) * 2011-02-18 2013-12-25 阿勒根公司 作为磷酸二酯酶10(pde10a)的抑制剂的取代的6,7-二烷氧基-3-异喹啉醇衍生物
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
HUP1100241A3 (en) 2011-05-06 2013-12-30 Richter Gedeon Nyrt Oxetane substituted pyrimidones
SG10201701101YA (en) 2012-04-02 2017-04-27 Cytokinetics Inc Methods for improving diaphragm function
CN111840294A (zh) 2012-04-11 2020-10-30 赛特凯恩蒂克公司 改善对骨骼肌疲劳的抵抗力的方法
AR091699A1 (es) * 2012-07-10 2015-02-25 Astellas Pharma Inc Derivado de indol carboxamida
HUE057533T2 (hu) 2014-04-29 2022-05-28 Cytokinetics Inc Eljárások vitálkapacitás csökkenésének gátlására
JP6573618B2 (ja) 2014-09-09 2019-09-11 アステラス製薬株式会社 尿失禁予防用及び／又は治療用新規医薬組成物
BR112018016475A2 (en) * 2016-02-12 2018-12-26 Cytokinetics, Incorporated tetrahydroisoquinoline derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102993204A (zh) * 2006-08-02 2013-03-27 赛特凯恩蒂克公司 特定的化学个体、组合物和方法
WO2009108332A1 (en) * 2008-02-27 2009-09-03 Vitae Pharmaceuticals, Inc. INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
An expedient synthesis of poly-substituted 1-arylisoquinolines from δ-ketonitriles via indium-mediated Barbier reaction protocol;Sung Hwan Kim等;《Tetrahedron Letters》;20090906;第50卷;第6476-6479页 *

Also Published As

Publication number Publication date
HRP20220655T1 (hr) 2022-06-24
PH12018501694A1 (en) 2019-01-28
US20170233402A1 (en) 2017-08-17
PH12018501694B1 (en) 2023-08-30
CO2018007920A2 (es) 2018-12-14
UA124879C2 (uk) 2021-12-08
US10689393B2 (en) 2020-06-23
AU2017217663A1 (en) 2018-10-04
CN113666938A (zh) 2021-11-19
RU2743424C2 (ru) 2021-02-18
US20230125280A1 (en) 2023-04-27
JP2021073270A (ja) 2021-05-13
US20200270266A1 (en) 2020-08-27
EP3413892A1 (en) 2018-12-19
EP3413892A4 (en) 2019-08-14
ZA201804947B (en) 2024-05-30
WO2017139526A8 (en) 2018-08-16
IL261055B (en) 2021-03-25
AR107592A1 (es) 2018-05-16
IL261055A (en) 2018-10-31
JP7137650B2 (ja) 2022-09-14
WO2017139526A1 (en) 2017-08-17
JP6832943B2 (ja) 2021-02-24
CN109069498A (zh) 2018-12-21
CY1125222T1 (el) 2025-03-28
SG11201806416XA (en) 2018-08-30
TW202138373A (zh) 2021-10-16
US9914741B2 (en) 2018-03-13
TW201741316A (zh) 2017-12-01
ES2913423T3 (es) 2022-06-02
US11479561B2 (en) 2022-10-25
DK3413892T3 (da) 2022-05-23
MX2018009759A (es) 2018-11-29
KR20180120701A (ko) 2018-11-06
SI3413892T1 (sl) 2022-06-30
CL2018002287A1 (es) 2019-01-04
MD3413892T2 (ro) 2022-06-30
JP2019509267A (ja) 2019-04-04
US20190194220A1 (en) 2019-06-27
RS63240B1 (sr) 2022-06-30
AU2017217663B2 (en) 2021-06-17
HUE058820T2 (hu) 2022-09-28
MX379159B (es) 2025-03-10
RU2018130002A3 (https=) 2020-03-24
CA3012839A1 (en) 2017-08-17
SMT202200201T1 (it) 2022-07-21
US10259821B2 (en) 2019-04-16
TWI719138B (zh) 2021-02-21
LT3413892T (lt) 2022-06-10
EP3413892B1 (en) 2022-04-20
PT3413892T (pt) 2022-05-30
US20180148458A1 (en) 2018-05-31
MA44018B1 (fr) 2022-05-31
TWI773118B (zh) 2022-08-01
BR112018016475A2 (en) 2018-12-26
MA44018A (fr) 2018-12-19
NZ746311A (en) 2022-08-26
EP4032877A1 (en) 2022-07-27
PL3413892T3 (pl) 2022-06-13
RU2018130002A (ru) 2020-03-12

Similar Documents

Publication Publication Date Title
JP7137650B2 (ja) テトラヒドロイソキノリン誘導体
CN110156786B (zh) 嘧啶并环化合物及其制备方法和应用
JPWO2001040227A1 (ja) トリアザスピロ［５．５］ウンデカン誘導体およびそれらを有効成分とする薬剤
CN111212842A (zh) 血管加压素受体拮抗剂以及与其相关的产品和方法
WO2023274246A1 (zh) 酰胺类化合物及其用途
CN121399103A (zh) 一类细胞程序性坏死抑制剂及其制备方法和用途
EP3333165B1 (en) Piperazine derivative
CN113272315B (zh) 一类类固醇化合物及其用途
HK40077141A (en) Tetrahydroisoquinoline derivative
HK40001944A (en) Tetrahydroisoquinoline derivatives
HK40001944B (en) Tetrahydroisoquinoline derivatives
WO2026012523A2 (zh) 钠通道调节剂
WO2023093787A1 (zh) 苯并二氮杂䓬类化合物及其作为Rho激酶抑制剂的应用
CN117430619A (zh) 吡唑并吡啶类化合物及其制备方法与应用
WO2024251133A1 (zh) 作为α5-GABAA受体调节剂的杂环化合物及其用途
HK1210166A1 (en) Fused tricyclic amide compounds as multiple kinase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210712

Address after: California, USA

Applicant after: CYTOKINETICS Inc.

Address before: Tokyo, Japan

Applicant before: Astellas Pharma Inc.

Applicant before: CYTOKINETICS Inc.

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210817